Aspect Biosystems and Novo Nordisk update on diabetes partnership

Danish pharma major Novo Nordisk (NOV: N) and privately-held Vancouver-based Aspect Biosystems today announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes.

Since 2023, Aspect and Novo Nordisk have collaborated to develop cellular medicines designed to replace, repair or supplement biological functions to deliver truly disease-modifying therapies. This new phase of the partnership builds on the momentum achieved in the existing collaboration. It reflects a shared mission to accelerate the development of potentially curative medicines for serious diseases.

Aspect has acquired rights to stem cell-derived islet cell and hypoimmune cell engineering technologies from Novo Nordisk and will lead development, manufacturing and commercialization. Novo Nordisk will have defined rights to expand its role in later-stage development and commercialisation.